North America is expected to hold
a dominant position in the cell expansion market due to increasing demand for
regenerative medicines and rising incidence of chronic diseases
Regional segmentation of the Cell
Expansion Market by Coherent Market Insights includes North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa. The cell expansion
market in North America is driven by the increasing demand for regenerative
medicines that are highly compatible with patients and offer rapid results. For
instance, the FDA is increasingly approving treatments involving cells derived
from bone or blood marrow, due to its well-established efficacy and safety.
Furthermore, increasing incidence of chronic diseases and rising R&D
investments for the development of cell-based products are other factors
expected to support growth of the cell expansion market. For instance in 2018,
according to the Centers for Disease Control and Prevention approximately 6 in
10 American citizen have at least one chronic diseases such as cancer,
diabetes, and others in the U.S.
According to a study published in
NIH report, around 500,000 people benefit from a transplant each year using
regenerative medicine in the U.S. Increasing R&D expenditure by several
companies for the development of new therapeutic products and availability of
untapped growth opportunities are expected to drive the cell expansion market
in Asia Pacific. For instance, according to the Indian Brand Equity Foundation
reports the Government of India the healthcare expenditure is approximately 1.4
% of total GDP in 2018 as compared to 1.2% in 2014.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1293
Cell expansion is the large scale
artificial production of daughter cells from a single cell, to support medical
research. Rising preference for regenerative medicines offering faster results,
and emergence of cell-based therapies with high patient compatibility are
expected to fuel the cell expansion market during the forecast period
(2017–2025). Regenerative medicine helps the body to form new functional tissue
to replace defective or lost ones providing treatment for conditions with
inadequate therapies. According to the U.S. Department of Health and Services,
in 2016, NIH invested around US$ 1.5 billion in stem cell research projects.
Increasing government and private sector expenditure on cell-based research
therapies is expected to boost growth of the market for cell expansion in the
near future. The number of FDA approvals for clinical trials of stem cell-based
treatments is rapidly increasing. According to a report published by
Pharmaceutical Research and Manufacturers of America, in 2013, around 69 cell
therapies with clinical trials were under review with the FDA. The therapeutic
classes represented in these trials include skin diseases, cardiovascular
diseases, transplantations, eye conditions, cancer and associated conditions,
musculoskeletal disorders, genetic disorders, and digestive disorders.
Increasing incidence of chronic
medical conditions is expected to boost growth of the cell expansion market
over the forecast period
The increasing cases of chronic
and rare medical conditions around the world is another key factor driving
demand for cell expansion. For instance, according to World Health Organization
(WHO), around 15 million people are projected to suffer from cancer by 2020.
The rising prevalence of cancer, is in turn, expected to boost growth of the
cell expansion market. Cell-based therapy is also a promising approach for
treating chronic kidney disease and is presently the focus of preclinical
studies.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/cell-expansion-market-1293
Recent advancements in
regenerative medicine and tissue engineering have created cell-based approaches
for the treatment of renal failure. Such treatments include biotechnological
approach using implantation of bioengineered kidney constructs, transplanting
cells, and bio-artificial renal systems. However, lack of high-tech
instrumentation and skilled workforce coupled with the high cost of operations
are expected to hamper growth of the cell expansion market.
Biotechnology merger and
acquisition (M&A) activities have also experienced a boost in the region.
According to investment bank China Renaissance, in 2016, 37 pharmaceutical and
biotech M&A deals worth US$ 6.8 billion were closed in China.
Major industry players use merger
and acquisitions as their major growth strategy
Key players operating in the cell
expansion market include Becton, Dickinson and Company, Beckman Coulter, Inc.,
Corning, Inc., GE Healthcare, Lonza, Merck KGaA (Sigma-Aldrich Co. LLC),
Miltenyi Biotec, Thermo Fisher Scientific, Inc., Terumo BCT, Inc., and Stemcell
Technologies, Inc. In July 2016, GE Healthcare acquired Biosafe SA, a Swiss
company that manufactures instruments that recover stem cells and help in
various other cell processing procedures related to personalized medicine. This
acquisition will help GE Healthcare to grow the cells in the sample for
appropriate dose sizes.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1293
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment